Murdo Gordon appointed Executive Vice President and Chief Commercial Officer, BMS

He will lead the company's Worldwide Markets in addition to a new Worldwide Commercialization team.

“Murdo has demonstrated tremendous success driving commercial excellence at BMS, and built strong relationships with our markets across the world,” said Caforio. “Murdo has made significant contributions to our success in immuno-oncology and Eliquis, and I am confident his leadership will help drive continued growth and deliver our medicines to more patients faster.”

Gordon joined BMS in 1989 and spent the first 14 years at the company in Canada where he held positions of increasing responsibility in sales and marketing. Gordon moved into the company’s US operations in 2003 where he held senior commercial leadership positions in cardiovascular, neuroscience and market access. He led strategy and commercial operations as senior vice president for US oncology and immunoscience from 2011 to 2013, and served as president, US from 2013 to 2015. Murdo is a member of the Board of Directors of RWJBarnabas Health and received a BSc in Cell and Molecular Biology from Concordia University, Montreal, and also attended the General Management Program, CEDEP at INSEAD, Fontainebleau, France.